PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
ConditionLung Cancer
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHansoh BioMedical R&D Company
About this trial
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Eligibility criteria
Qualifiers
Locally advanced or metastastic NSCLC;
Received at least 1 line SoC,or treatment naïve;
With at least 1 target lesion according to RECIST 1.1.
Appropriate organ function
Disqualifiers
Insufficient wash out duration of prior systemic anticancer therapy
Local radiotherapy within 2 weeks prior to first dose of investigational drug
Pleural/abdominal effusion requires clinical intervention
Major surgery within 4 weeks prior to first dose of investigational drug
Trial design
Treatments tested in this trial
- HS-20122+Aumolertinib
- HS-20122+Adbrelimab
- HS-20122+Adbrelimab+Platinum-based Chemo
Treatment groups
396 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov